Nuwellis, Inc. (NUWE)

NASDAQ: NUWE · Real-Time Price · USD

0.7809

+0.0462 (6.29%)

At close: Sep 4, 2026, 4:00 PM EDT

0.7755

-0.0054 (-0.69%)

After-hours: Sep 4, 2026, 7:59 PM EDT

Market Cap	2.85M -35.9%
Revenue (ttm)	9.01M +8.4%
Net Income	-11.32M
EPS	-145.78
Shares Out	3.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,486
Open	0.7500
Previous Close	0.7347
Day's Range	0.7422 - 0.7823
52-Week Range	0.7112 - 183.0500
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About NUWE

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Pra... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1999

Employees 38

Stock Exchange NASDAQ

Ticker Symbol NUWE

Website https://www.nuwellis.com

Full Company Profile

Financial Performance

In 2025, Nuwellis's revenue was $8.27 million, a decrease of -5.38% compared to the previous year's $8.74 million. Losses were -$17.52 million, 64.9% more than in 2024.

Financial Statements

News

Nuwellis, Atrility Medical announce AtriAmp co-promotion and distribution pact

Nuwellis (NUWE) and Atrility Medical announced that they have entered into a co-promotion and distribution agreement for Atrility’s AtriAmp device. Under the agreement, the companies will begin an ini...

12 days ago - TheFly

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis' pediatric and critical care portfolio and prov...

12 days ago - GlobeNewsWire

Nuwellis Slides: Investor presentation

Nuwellis has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.

12 days ago - Filings

Nuwellis files to sell 1.35M shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.35M shares of common stock. The company is not selling any…

18 days ago - TheFly

Nuwellis Registration statement: Registration filing

Nuwellis filed a registration statement on August 18, 2026, providing details about a securities offering with the SEC.

19 days ago - Filings

Nuwellis Earnings Call Transcript: Q2 2026

Revenue grew 14% year-over-year in Q2 2026, with gross margin rising to 76% and net loss narrowing to $4.8 million. Strategic focus remains on expanding Aquadex utilization, pediatric and critical care growth, and disciplined capital allocation.

24 days ago - Transcripts

Nuwellis Earnings release: Q2 2026

Nuwellis released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.

24 days ago - Filings

Nuwellis Quarterly report: Q2 2026

Nuwellis has published its Q2 2026 quarterly earnings report on August 13, 2026.

24 days ago - Filings

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwel...

24 days ago - GlobeNewsWire

Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced t...

4 weeks ago - GlobeNewsWire

Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications

Development initiatives to strategically extend Aquadex® platform capabilities for future immunomodulation, extracorporeal blood purification, and advanced critical care therapies Development initiati...

4 weeks ago - GlobeNewsWire

Nuwellis prices $3.4M at-the-market offering at $2.59 per share

Nuwellis (NUWE) announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common...

5 weeks ago - TheFly

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public Offering Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warran...

5 weeks ago - GlobeNewsWire

Why Is Penny Stock Nuwellis (NUWE) Up Today?

Nuwellis stock was on the rise after the company announced a study that was published in a peer-reviewed journal.

5 weeks ago - TipRanks

Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

Peer-reviewed research demonstrates epoprostenol maintained circuit performance without observed bleeding events or increased vasoactive support in critically ill pediatric patients Peer-reviewed rese...